Drug intelligence / Profile preview

scopolamine + thyrotropin-releasing hormone

Development stage: Preclinical
Modality: Peptides, Small Molecules
Administration: Intravenous

Overview

A combination of scopolamine (an anticholinergic agent) and thyrotropin-releasing hormone (TRH, a tripeptide neuromodulator) used primarily in research settings to study cognitive function and cholinergic system interactions. In young subjects, TRH has been shown to attenuate scopolamine-induced memory impairment, while in older subjects and Alzheimer's patients, the interaction produces different effects. Scopolamine appears to attenuate the pressor (blood pressure raising) effect of TRH.

Targets

mAChR (Muscarinic acetylcholine receptors)TRHR (Thyrotropin-releasing hormone receptor)

Beyond the preview

Go deeper on scopolamine + thyrotropin-releasing hormone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scopolamine + thyrotropin-releasing hormone.

Explore the full profile